Wednesday, January 01, 2020 9:50:43 AM
Q1-FY2018 REVS > $348,000
Q2-FY2018 REVS > $448,000
Q3-FY2018 REVS > $586,000
Q4-FY2018 REVS > $715,000
Q1-FY2019 REVS > $1,200,000
Q2-FY2019 REVS > $2,600,000
Given how rapidly this trajectory of REVS is accelerating
future qtrs. could look like the following >
Q3-FY2019 REVS > $4,000,000
Q4 FY2019 REVS > $5,500,000
That would be a total of $13,300,000 REVS for FY 2019 !!
Q1-FY2020 REVS > $7,500,000
Q2-FY2020 REVS > $10,000,000
Q3-FY2020 REVS > $12,500,000
Q4-FY2020 REVS > $15,000,000
That would be a total of $45,000,000 REVS for FY2020 !!
Given AXXA should have close to $500M ASSETS
by end of FY2020 and be FULLY AUDITED and trading on
a HIGHER EXCHANGE AXXA should trade at a conservative
mkt valuation of 2X its $45M REVS that would be a
mkt cap of $90M so with aprox 450M O/S shrs that would be
a stock price of $$$ .20 $$$ sometime around the end of 2020
or early 2021...
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM